FY2025 EPS Estimates for AQST Boosted by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has increased its FY2025 earnings per share (EPS) estimate for Aquestive Therapeutics from ($0.64) to ($0.56), while the consensus estimate stands at ($0.46) per share.
• The recent quarterly earnings report showed a loss of ($0.14) EPS, which surpassed analysts' expectations of ($0.18), despite revenue falling short of estimates.
• Aquestive Therapeutics has received multiple ratings from analysts, including a "buy" from HC Wainwright and "outperform" from Oppenheimer, with a consensus target price of $10.14.

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - Equities research analysts at Cantor Fitzgerald boosted their FY2025 earnings per share (EPS) estimates for Aquestive Therapeutics in a report released on Tuesday, August 19th. Cantor Fitzgerald analyst K. Kluska now expects that the company will post earnings per share of ($0.56) for the year, up from their previous forecast of ($0.64). The consensus estimate for Aquestive Therapeutics' current full-year earnings is ($0.46) per share. Cantor Fitzgerald also issued estimates for Aquestive Therapeutics' FY2026 earnings at ($0.57) EPS.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last issued its earnings results on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.18) by $0.04. The company had revenue of $10.00 million for the quarter, compared to the consensus estimate of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS.

A number of other equities analysts have also recently issued reports on AQST. HC Wainwright restated a "buy" rating and set a $10.00 target price on shares of Aquestive Therapeutics in a report on Tuesday, June 17th. Zacks Research upgraded Aquestive Therapeutics from a "strong sell" rating to a "hold" rating in a report on Wednesday, August 13th. Finally, Oppenheimer began coverage on Aquestive Therapeutics in a report on Monday, June 2nd. They set an "outperform" rating and a $7.00 target price on the stock. Seven investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $10.14.

Aquestive Therapeutics Trading Up 0.8%

Shares of AQST opened at $3.88 on Thursday. Aquestive Therapeutics has a 1 year low of $2.12 and a 1 year high of $5.80. The stock has a market cap of $386.91 million, a P/E ratio of -5.54 and a beta of 1.99. The stock's 50-day moving average price is $3.79 and its two-hundred day moving average price is $3.17.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Modern Wealth Management LLC acquired a new stake in Aquestive Therapeutics in the 2nd quarter valued at approximately $33,000. BNP Paribas Financial Markets raised its position in Aquestive Therapeutics by 78.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company's stock valued at $31,000 after buying an additional 4,134 shares during the last quarter. Jane Street Group LLC acquired a new stake in Aquestive Therapeutics in the 2nd quarter valued at approximately $217,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Aquestive Therapeutics by 6.0% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,098 shares of the company's stock valued at $156,000 after buying an additional 2,649 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its position in Aquestive Therapeutics by 16.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 32,073 shares of the company's stock valued at $106,000 after buying an additional 4,557 shares during the last quarter. Institutional investors and hedge funds own 32.45% of the company's stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.